Literature DB >> 7930610

Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.

J P Valensi1, J R Carlson, G A Van Nest.   

Abstract

We have studied serum cytokine profiles in BALB/c mice after immunization with influenza vaccine alone or combined with the following adjuvants: alum; MF59 emulsion; MF59 containing the muramyl peptide N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2- dipalmitoyl-sn-glycero-3-(hydroxyphosphoryloxy)) ethylamide (MTP-PE); MF59 plus the lipid A analogue monophosphoryl lipid A; MF59 plus the Quil A saponin fraction LTC; or LTC alone. Pooled mouse sera were analyzed by ELISA at various times after immunization for IL-1 alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IFN-gamma, and TNF-alpha. In naive mice, vaccine alone induced low levels of IL-3 and IL-5 only; vaccine plus alum induced a low IL-6 response as well. The MF59-based adjuvants significantly increased the IL-5 and IL-6 levels, whereas Quil A LTC induced strong IFN-gamma and measurable IL-2 responses, in addition to moderate IL-5 and IL-6. In previously infected mice, MF59 and MF59/MTP-PE were capable of generating IFN-gamma responses, as well as IL-5 and IL-6. All of the cytokine responses were rapid (peaking 3 to 12 h postimmunization) and short lived. In naive mice, the MF59 adjuvants induced serum cytokine profiles that are consistent with a primarily Th2-type response, whereas the Quil A LTC induced cytokines associated with both Th1 and Th2 responses. Ab analyses indicated that, although the adjuvants strongly affected the magnitude of the humoral response, there was no obvious correlation between the cytokine profile observed and the subclasses of Ab induced.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930610

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

2.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

Authors:  Yoshikazu Honda-Okubo; Fadi Saade; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-20       Impact factor: 3.641

3.  Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice.

Authors:  Michael S Petrik; Margaret C Wong; Rena C Tabata; Robert F Garry; Christopher A Shaw
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

4.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

5.  A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.

Authors:  Feng Liu; Xiangjie Sun; Jeffery Fairman; David B Lewis; Jacqueline M Katz; Min Levine; Terrence M Tumpey; Xiuhua Lu
Journal:  Virology       Date:  2016-03-21       Impact factor: 3.616

6.  Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes.

Authors:  M Villacres-Eriksson
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

7.  Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin-15 but not interleukin-1β responses.

Authors:  Sapna Patel; Archana Akalkotkar; Joseph J Bivona; Ji-Young Lee; Young-Ki Park; Mingke Yu; Sara L Colpitts; Michael Vajdy
Journal:  Immunology       Date:  2016-06-22       Impact factor: 7.397

8.  A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Authors:  William M Gwinn; Brandi T Johnson; Shaun M Kirwan; Ashley E Sobel; Soman N Abraham; Michael D Gunn; Herman F Staats
Journal:  Vaccine       Date:  2013-01-23       Impact factor: 3.641

Review 9.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

10.  A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines.

Authors:  Million A Tegenge; Robert J Mitkus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-04       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.